HIV-positive persons with CD4 cell counts <300 cells/μL should receive three doses of HAV vaccine over 6–12 months instead of the standard two [198]. 6.2.6 In the absence of obstetric

complications, normal vaginal delivery can be recommended if the mother is receiving HAART. Grading: 2C As HCV antiviral therapy is contraindicated in pregnant women due to possible teratogenicity, mode of delivery remains Selleck Dasatinib the only possible risk factor amenable to intervention. No randomized studies of CS compared to normal vaginal delivery to prevent HCV MTCT have been performed. In mono-infection, two meta-analyses failed to show a significant decrease in HCV vertical transmission among mothers in the study who underwent CS compared with mothers who gave birth vaginally (OR 1.1 [199] to OR 1.19 [183]). In the first European Paediatric Hepatitis Network cohort, a subgroup analysis of women coinfected with HIV (n = 503,

35.4%) demonstrated a reduced risk of vertical transmission of HCV with CS (OR 0.43; 95% CI 0.23–0.80) [183]. However, in a later analysis from the European Paediatric Hepatitis Network (n = 208, 15.0%) no such association was found (OR 0.76; 95% CI 0.23–2.53) [188]. In the later analysis, MTCT of HCV was less (8.7% vs. 13.9%) and more women probably received HAART (41%), which was associated with a significant HCV VL reduction compared to those who received monotherapy or no therapy (OR 0.26; 95% CI 0.07–1.01). There was also a trend to lower HCV VL in this group, which may go some way to explaining this. Also, in a small French cohort of coinfected Panobinostat research buy women (29% on HAART), rate of transmission did not differ significantly between children born by vaginal delivery or CS [200]. HAART should be given to all HCV/HIV coinfected pregnant women, regardless of CD4 cell count or HIV VL because of the evidence of increased HIV transmission in coinfected mothers. 6.2.7 Where the CD4 cell count is <500 cells/μL, HAART should be continued if active HCV coinfection exists because of the increased risk of progressive HCV-related liver disease. Grading: 1B 6.2.8 Where the CD4 cell count is >500 cells/μL

and there is no HCV viraemia or fibrosis, HAART should be discontinued. Grading: 2C 6.2.9 Where the CD4 cell count is >500 cells/μL and there is HCV viraemia and evidence of liver inflammation or fibrosis, continuing Phosphatidylinositol diacylglycerol-lyase HAART is preferable because of a benefit on fibrosis progression. Grading: 2B 6.2.10 Where the CD4 cell count is between 350 and 500 cells/μL and there is no evidence of viraemia, inflammation or fibrosis, continuing HAART is preferable if the patient displays a preference to do so. Grading: 2C The decision to continue ART or not postpartum depends on both HIV and HCV factors. There is consensus among guidelines that all persons with active (HCV-viraemic) coinfection should receive HAART if their CD4 cell count is <500 cells/μL [154],[201],[202].